Form 4: Aurinia Pharmaceuticals Director, Jeffrey Allen Bailey, Reports Stock Option Grant

Director Jeffrey Allen Bailey reports receiving a stock option grant from Aurinia Pharmaceuticals Inc.

Summary

• Jeffrey Allen Bailey, a director of Aurinia Pharmaceuticals Inc., filed a Form 4 with the SEC.
• The filing reports a transaction date of May 16, 2025.
• Bailey was granted a director stock option to buy 37,485 common shares at a price of $8.15 per share.
• The options vest one year from the date of grant and expire on May 16, 2035.
• Following the transaction, Bailey directly owns options for 37,485 common shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation plans.
• The size of the grant (37,485 shares) would need to be compared to the overall compensation structure and company size to determine if it is in line with industry norms.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, Stock Options, Director, Beneficial Ownership, Aurinia Pharmaceuticals, AUPH, SEC Filing